Natixis Advisors LLC Buys 4,390 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis Advisors LLC raised its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 10.6% in the 4th quarter, Holdings Channel reports. The firm owned 45,713 shares of the medical research company’s stock after acquiring an additional 4,390 shares during the period. Natixis Advisors LLC’s holdings in Bio-Rad Laboratories were worth $15,017,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Metis Global Partners LLC lifted its position in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares in the last quarter. Avior Wealth Management LLC raised its holdings in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after acquiring an additional 32 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock valued at $296,000 after acquiring an additional 34 shares during the last quarter. Finally, CIBC Asset Management Inc grew its holdings in shares of Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock valued at $234,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 1.2 %

BIO stock opened at $260.16 on Wednesday. The firm’s fifty day simple moving average is $308.56 and its two-hundred day simple moving average is $326.91. The stock has a market capitalization of $7.29 billion, a price-to-earnings ratio of -4.00 and a beta of 0.98. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a twelve month low of $244.00 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BIO shares. Wells Fargo & Company decreased their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.